What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences

Background: The potential value of patient preference studies has been recognized in clinical individual treatment decision-making between clinicians and patients, as well as in upstream drug decision-making. Drug developers, regulators, reimbursement and Health Technology Assessment (HTA) bodies ar...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Serena Petrocchi, Rosanne Janssens, Serena Oliveri, Reinhard Arnou, Ilaria Durosini, Paolo Guiddi, Evelyne Louis, Marie Vandevelde, Kristiaan Nackaerts, Meredith Y. Smith, Giulia Galli, Filippo de Marinis, Letizia Gianoncelli, Gabriella Pravettoni, Isabelle Huys
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2021-03-01
סדרה:	Frontiers in Pharmacology
נושאים:	patient preferences drug decision-making drug development patient-centered research lung cancer benefit-risk assessment
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fphar.2021.602112/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!